Surekha Yadav

PSMA PET/CT–Derived Indicators and Outcomes After [ 177 Lu]Lu-PSMA-617: A Multicenter Retrospective Analysis from the U.S. Expanded-Access Program

Koichiro Kimura, Vishnu Murthy, Andrew F. Voter, Lilja B. Sólnes et autres

Pretherapeutic visual and quantitative indicators derived from prostate-specific membrane antigen (PSMA) PET/CT have been proposed as predictors of response to [177Lu]Lu-PSMA-617 (177Lu-PSMA) therapy in patients with metastatic castration-resistant prostate cancer. This study aimed to evaluate and compare the prognostic performance of these …

us, de (code pays fourni par la source)

Assessment of PSMA PET/CT derived predictive markers for 177 Lu-PSMA-617 treatment outcomes: Results from the U.S. Expanded-Access program.

Koichiro Kimura, Vishnu Murthy, Andrew F. Voter, Abuzar Moradi Tuchayi et autres

5079 Background: 177 Lu-PSMA-617 (Lu-PSMA) contributes to prolong progression-free survival (PFS) and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients who progressed after chemotherapy. Pretherapeutic prostate-specific membrane antigen (PSMA) PET/CT information can be used to predict Lu-PSMA therapy response patterns …

us (code pays fourni par la source)

Can177Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data

Azadeh Akhavanallaf, Zhong‐Lin Lu, Avery Peterson, Johan Blakkisrud et autres

Before performing 177Lu-DOTATATE therapy for neuroendocrine tumors, somatostatin receptor (SSTR) PET imaging is currently used to confirm sufficient tumor SSTR expression, but it also has potential to be used to personalize treatment by predicting absorbed doses to critical organs. This study aims …

us, no, ca, se (code pays fourni par la source)

Pre- or post-chemotherapy: effect on PSMA uptake

Surekha Yadav, Abuzar Moradi Tuchayi, Moein Moradpour, Fei Jiang et autres

Despite multiple therapies that delay disease progression and prolong life, metastatic castration-resistant prostate cancer (mCRPC) remains the second leading cause of cancer related death in American men [ 1 , 2 ]. Radioligand therapy (RLT) targeting Prostate Specific Membrane Antigen (PSMA) has …

us (code pays fourni par la source)

Peptide receptor radionuclide therapy with 177 Lu-DOTATATE: a single center experience

Tuchayi Abuzar Moradi, Rebecca Mirro, Moein Moradpour, Surekha Yadav et autres

Impact of Posttreatment SPECT/CT on Patient Management During 177 Lu-PSMA-617 Radiopharmaceutical Therapy

Surekha Yadav, Blair Lowery, Abuzar Moradi Tuchayi, Fei Jiang et autres

177Lu can be imaged after administration using SPECT/CT. Most work to date has focused on using posttreatment imaging to measure normal organ and tumor dose. We aimed to assess the impact of posttreatment SPECT/CT on the management of patients undergoing 177Lu-prostate-specific membrane …

us (code pays fourni par la source)

Comparison of 18F-DCFPyL and 68Ga-PSMA-11 for 177Lu-PSMA-617 therapy patient selection

Surekha Yadav, Sarasa T. Kim, Abuzar Moradi Tuchayi, Fei Jiang et autres

Purpose 68Ga-PSMA-11 is recommended for the selection of patients for treatment in the package insert for 177Lu-PSMA-617. We aimed to compare imaging properties and post-treatment outcomes from radioligand therapy (RLT) of patients selected with 68Ga-PSMA-11 and 18F-DCFPyL. Methods We retrospectively evaluated 80 …

us (code pays fourni par la source)

Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection

Surekha Yadav, Fei Jiang, Sara Kurkowska, Rachelle Saelee et autres

Understanding the relationship between lesion-absorbed dose and tumor response in 177Lu-PSMA-617 radiopharmaceutical therapies (RPTs) remains complex. We aimed to investigate whether baseline lesion-absorbed dose can predict lesion-based responses and to explore the connection between lesion-absorbed dose and prostate-specific antigen (PSA) response. Methods: …

us, pl, ca (code pays fourni par la source)

68 Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18 F-FDG

Brad Kline, Surekha Yadav, Youngho Seo, Robin Cumming Ippisch et autres

Fibroblast activation protein (FAP), expressed in the tumor microenvironment of a variety of cancers, has become a target of novel PET tracers. The purpose of this report is to evaluate the imaging characteristics of 68Ga-FAP-2286, present the first—to our knowledge—dosimetry analysis to …

us (code pays fourni par la source)

Real-World Experience with177Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval

Abuzar Moradi Tuchayi, Surekha Yadav, Fei Jiang, Sarasa T. Kim et autres

We report our initial real-world experience with 177Lu-PSMA-617 radioligand therapy. Methods: We performed a retrospective review of patients treated with 177Lu-PSMA-617. Pretreatment PSMA PET, laboratory findings, overall survival, a fall in prostate-specific antigen by 50% (PSA50), and toxicities were evaluated. Results: Ninety-nine …

us (code pays fourni par la source)

The Impact of Posttreatment Imaging in Peptide Receptor Radionuclide Therapy

Surekha Yadav, Courtney A. Lawhn-Heath, Alan T. Paciorek, Sheila Lindsay et autres

Posttreatment imaging of γ-emissions after peptide receptor radionuclide therapy (PRRT) can be used to perform quantitative dosimetry as well as assessment response using qualitative measures. We aimed to assess the impact of qualitative posttreatment imaging on the management of patients undergoing PRRT. …

us (code pays fourni par la source)